Antibody cocktail therapy establishes a high barrier to development of treatment resistance while providing a protective therapy for the population at large. If approved, it is anticipated that COVI- Shield will be offered for administration as a prophylactic for those returning to work and as a therapeutic to those who have been exposed to SARS-CoV-2. COVI- Shield prevention and treatment is designed to be administered as often as necessary, with each dose expected to provide antiviral protection for up to two months.
ContractPharma
No comments:
Post a Comment